{
  "actions": [
    {
      "acted_at": "2024-05-07",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2024-05-07",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2024-05-07",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "text": "Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2024-05-10",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    },
    {
      "acted_at": "2024-12-17",
      "action_code": "",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr8267-118",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "02"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "118",
  "cosponsors": [
    {
      "bioguide_id": "P000048",
      "district": "11",
      "name": "Pfluger, August",
      "original_cosponsor": true,
      "sponsored_at": "2024-05-07",
      "state": "TX",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2024-05-07",
  "number": "8267",
  "official_title": "To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Old Drugs, New Cures Act",
  "sponsor": {
    "bioguide_id": "D000230",
    "district": "1",
    "name": "Davis, Donald G.",
    "state": "NC",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2024-05-07",
  "subjects": [
    "Health"
  ],
  "subjects_top_term": "Health",
  "summary": null,
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Old Drugs, New Cures Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Old Drugs, New Cures Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend titles XVIII and XIX of the Social Security Act to provide that priority research drugs shall not be treated as line extensions of existing drugs for purposes of calculating manufacturer rebates under the Medicare and Medicaid programs, and for other purposes.",
      "type": "official"
    }
  ],
  "updated_at": "2024-12-19T09:06:21Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/118/hr/BILLSTATUS-118hr8267.xml"
}